Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model

Cancer Nanotechnology

Volumn 2, Issue 1-6, 2011, Pages 67-79

  Perumal, Venkatesan ^a,b   Banerjee, Shubhadeep ^a   Das, Shubasis ^a   Sen, R K ^a   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b PSG INSTITUTE OF ADVANCED STUDIES   (India)

Author keywords

Celecoxib; Colon cancer; Cytotoxicity; Hemocompatibilty; Liposomes

Indexed keywords

CELECOXIB; LIPID PEROXIDE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; BLOOD COMPATIBILITY; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; LIPOSOMAL DELIVERY; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 81555215182     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-011-0017-5     Document Type: Article

References (46)

1. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H (2009) Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release 137: 8-14.
2. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, McLeod HL (2008) Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 44: 1754-1760.
3. Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F (2007) Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. PDA J Pharm Sci Technol 61: 276-285.
4. Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ, Boven E (2008) Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. Biochem Pharmacol 75: 427-437.
5. Caddeo C, Teskac K, Sinico C, Kristl J (2008) Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 363: 183-191.
6. Celia C, Malara N, Terracciano R, Cosco D, Paolino D, Fresta M, Savino R (2008) Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells. Nanomedicine 4: 155-166.
7. Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V (2009) Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J Control Release 133: 11-17.
8. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW (2008) Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 7: 897-904.
9. Docheva D, Padula D, Popov C, Mutschler W, Clausen-Schaumann H, Schieker M (2008) Researching into the cellular shape, volume and elasticity of mesenchymal stem cells, osteoblasts and osteosarcoma cells by atomic force microscopy. J Cell Mol Med 12: 537-552.
10. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51: 691-743.
11. Egawa H, Furusawa K (1999) Liposome adhesion on mica surface studied by atomic force microscopy. Langmuir 15: 1660-1666.
12. Gaiser T, Becker MR, Habel A, Reuss DE, Ehemann V, Rami A, Siegelin MD (2008) TRAIL-mediated apoptosis in malignant glioma cells is augmented by celecoxib through proteasomal degradation of survivin. Neurosci Lett 442: 109-113.
13. Glaser R, Mumaw V, Farrugia R, Munger B (1977) Scanning electron microscopy of the surfaces of hamster embryo cells transformed by herpes simplex virus. Cancer Res 37: 4420-4422.
14. Guggi D, Langoth N, Hoffer MH, Wirth M, Bernkop-Schnurch A (2004) Comparative evaluation of cytotoxicity of a glucosamine-TBA conjugate and a chitosan-TBA conjugate. Int J Pharm 278: 353-360.
15. Hiremath PS, Soppimath KS, Betageri GV (2009) Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 380: 96-104.
16. Hodges GM (1970) A scanning electron microscope study of cell surface and cell contacts of "spontaneously" transformed cells in vitro. Eur J Cancer 6: 235-239.
17. Hsiao PW, Chang CC, Liu HF, Tsai CM, Chiu TH, Chao JI (2007) Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicol Appl Pharmacol 222: 97-104.
18. Huggins C, Grand LC, Brillantes FP (1961) Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression. Nature 189: 204-207.
19. Jacobs JB, Arai M, Cohen SM, Friedell GH (1976) Early lesions in experimental bladder cancer: scanning electron microscopy of cell surface markers. Cancer Res 36: 2512-2517.
20. Jung SH, Seong H, Cho SH, Jeong KS, Shin BC (2009) Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity. Int J Pharm 382: 254-261.
21. Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N (2008) Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3, 5-dimethyl-1H-pyrrol-2-ylmethylene)-1, 3-dihydro-indol-2-one, SU5416. Cancer Lett 270: 260-268.
22. Li Q, Peng J, Zhang GY (2008) Effect of a selective COX-2 inhibitor on cell proliferation and apoptosis in human gastric cancer cell line BGC-823. Zhong Nan Da Xue Xue Bao Yi Xue Ban 33: 1123-1128.
23. Ling YH, Liebes L, Zou Y, Perez-Soler R (2003) Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem 278: 33714-33723.
24. Lu Y, Li J, Wang G (2008) In vitro and in vivo evaluation of mPEG-PLA modified liposomes loaded glycyrrhetinic acid. Int J Pharm 356: 274-281.
25. Maier TJ, Schilling K, Schmidt R, Geisslinger G, Grosch S (2004) Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 67: 1469-1478.
26. Malejka-Giganti D, Niehans GA, Reichert MA, Bliss RL (2000) Post-initiation treatment of rats with indole-3-carbinol or beta-naphthoflavone does not suppress 7, 12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis. Cancer Lett 160: 209-218.
27. Mazhar D, Ang R, Waxman J (2006) COX inhibitors and breast cancer. Br J Cancer 94: 346-350.
28. Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW (2006) Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 5: 329-336.
29. Munoz-Bonilla A, Ibarboure E, Papon E, Rodriguez-Hernandez J (2009) Self-organized hierarchical structures in polymer surfaces: self-assembled nanostructures within breath figures. Langmuir 25: 6493-6499.
30. Nakano K, Tozuka Y, Yamamoto H, Kawashima Y, Takeuchi H (2008) A novel method for measuring rigidity of submicron-size liposomes with atomic force microscopy. Int J Pharm 355: 203-209.
31. Paulson SK, Zhang JY, Breau AP, Hribar JD, Liu NW, Jessen SM, Lawal YM, Cogburn JN, Gresk CJ, Markos CS, Maziasz TJ, Schoenhard GL, Burton EG (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab Dispos 28: 514-521.
32. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, Maziasz TJ, Cook CS, Karim A (2001) Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 297: 638-645.
33. Sadzuka Y, Takabe H, Sonobe T (2005) Liposomalization of SN-38 as active metabolite of CPT-11. J Control Release 108: 453-459.
34. Saha RN, Sajeev C, Jadhav PR, Patil SP, Srinivasan N (2002) Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography. J Pharm Biomed Anal 28: 741-751.
35. Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73: 1318-1329.
36. Samy RP, Gopalakrishnakone P, Ignacimuthu S (2006) Anti-tumor promoting potential of luteolin against 7, 12-dimethylbenz(a)anthracene-induced mammary tumors in rats. Chem Biol Interact 164: 1-14.
37. Singh A, Shukla Y (1998) Antitumour activity of diallyl sulfide on polycyclic aromatic hydrocarbon-induced mouse skin carcinogenesis. Cancer Lett 131: 209-214.
38. Storm G, Roerdink FH, Steerenberg PA, de Jong WH, Crommelin DJ (1987) Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Cancer Res 47: 3366-3372.
39. Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR (2010) The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma model. Biomaterials 31: 541-551.
40. Turanek J, Wang XF, Knotigova P, Koudelka S, Dong LF, Vrublova E, Mahdavian E, Prochazka L, Sangsura S, Vacek A, Salvatore BA, Neuzil J (2009) Liposomal formulation of alpha-tocopheryl maleamide: in vitro and in vivo toxicological profile and anticancer effect against spontaneous breast carcinomas in mice. Toxicol Appl Pharmacol 237: 249-257.
41. Venkatesan P, Das S, Krishnan MM, Chakraborty C, Chaudhury K, Mandal M (2010) Effect of AEE788 and/or Celecoxib on colon cancer cell morphology using advanced microscopic techniques. Micron 41: 247-256.
42. Wei W, Ma GH, Hu G, Yu D, McLeish T, Su ZG, Shen ZY (2008) Preparation of hierarchical hollow CaCO3 particles and the application as anticancer drug carrier. J Am Chem Soc 130: 15808-15810.
43. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD (2007) Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338: 317-326.
44. Yang X, Zhao X, Phelps MA, Piao L, Rozewski DM, Liu Q, Lee LJ, Marcucci G, Grever MR, Byrd JC, Dalton JT, Lee RJ (2009) A novel liposomal formulation of flavopiridol. Int J Pharm 365: 170-174.
45. Yuan Y, Liu C, Qian J, Wang J, Zhang Y (2010) Size-mediated cytotoxicity and apoptosis of hydroxyapatite nanoparticles in human hepatoma HepG2 cells. Biomaterials 31: 730-740.
46. Zhang L, Gao H, Chen L, Wu B, Zheng Y, Liao R, Jiang Y, He F (2008) Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett 269: 26-36.